Skip to main content
. 2016 Apr 28;114(10):1084–1089. doi: 10.1038/bjc.2016.107

Table 3. Severe immune-related adverse events.

  Pembrolizumab, N=26 (65%) Nivolumab, N=14 (35%) Ipilimumab, N=40
Grade 3/4 irAEs–no. (%) 3 (8) 14 (35%)
  Hypothyroidism–1 Colitis/diarrhoea–9
  Panhypopituitarism–1 Pneumonitis–3
  Bullous pemphigoid–1 Hepatitis–2
    Encephalitis–1

Abbreviation: irAE=immune-related adverse event.